Outsourcing

PCI Pharma Services expanded capacity of its commercial packaging site in Illinois.

Radha Iyer, vice-president and head of Quality and Scientific Affairs, Global Developed Markets, Dr. Reddy’s Laboratories, discusses new initiatives at the company.

Company launches new services dedicated to emerging biotech and biopharma companies.

Suppliers address the complexity of supplying disposable components for single-use systems to the global biopharmaceutical manufacturing industry.

Single-use components for biopharmaceutical manufacturing have a lower environmental impact than reusable components, but disposal is still a consideration.

SGS announces expansion of cell bank and bulk harvest testing services.

CDMO leader Marc Funk will succeed Ridinger as CEO of Lonza.

The company is set to expand biologics and fill/finish capacity at its biologics manufacturing sites in Madison, WI, and Bloomington, IN.

Fujifilm increases capacity of its Bio-CDMO business with an expansion of production in North Carolina.

The Massachusetts site, formerly associated with an affiliate of Shire, is Rentschler Biopharma’s first facility in the US.

Outsourcing of manufacturing activities is expected to increase in 2019.

The company is investing approximately $14 million to expand biologics packaging capabilities and capacity at its biologics manufacturing facility in Bloomington, IN.

CMOs and CDMOs made investments in new and expanded facilities and services in the last quarter of 2018.

Success depends on supplier communication and transparency, but it’s up to buyers to demand the right information and to look at the vendor’s overall business.

ADC Biotechnology will invest downstream formulation, fill/finish capabilities, and Lock-Release conjugation technology.

The expansion adds new capabilities and enhances existing service offerings for both oral and parenteral dosage forms.

Survey results and record attendance may show positive signs for established and emerging biopharma regions.

The growth in adoption of single-use systems for commercial manufacturing will be dramatic in coming years.

A project funded by BioProNET will investigate optimization for bioprocessing of gene therapy vectors using hydrodynamic fluid flow fields.

The company will complete an expansion of its secondary packaging capabilities at its Ravensburg, Germany site by 2020.

As biopharma companies rapidly change their focus, they may lack the laboratory space, instrumentation, and the scientific knowledge to support biologics research.

The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.

Industry experts discuss the formulation and development issues that should be considered when addressing scale up from small-scale batches to commercial production.

While food, shelter, and clothing are the primal essentials for life, hope-as embodied by modern medicine-has now become part of that human expectation.

The sterile-manufacturing contract development manufacturing organization is approved by FDA for viral vector manufacturing fill/finish processing at its biologics facility in Scotland, UK.

BeiGene is set to build late-stage clinical and commercial production capacity for cancer monoclonal antibodies with GE Healthcare’s KUBio, the prefabricated biopharma facility based on single-use technologies.

Sharing of bioprocessing know-how can help resolve pressing industry problems.

Partnerships, mergers, and new services indicate that biologics are continuing to influence CMOs’ and CDMOs’ decisions to expand their biopharmaceutical services.

The acquisition strengthens Nelson Labs’ outsourced testing capabilities for the pharmaceutical and medical device industries.

The company is certified as a manufacturer of pressure vessels and components for use in China.